
Parabilis Medicines, Inc. (NASDAQ:PBLS – Free Report) – Stock analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Parabilis Medicines in a report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($2.12) for the year, down from their prior forecast of ($2.10). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Parabilis Medicines’ current full-year earnings is ($2.60) per share. HC Wainwright also issued estimates for Parabilis Medicines’ Q4 2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.42) EPS, Q4 2027 earnings at ($0.44) EPS and FY2027 earnings at ($1.66) EPS.
Other equities analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage on shares of Parabilis Medicines in a research note on Monday, November 9th. They issued a “buy” rating and a $39.00 price target on the stock. Weiss Ratings cut shares of Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.80.
View Our Latest Report on Parabilis Medicines
Parabilis Medicines Stock Up 0.1%
Shares of NASDAQ:PBLS opened at $28.45 on Tuesday. The firm’s fifty day moving average is $30.63. Parabilis Medicines has a 1-year low of $22.66 and a 1-year high of $42.49.
Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.04. The company had revenue of $2.11 million during the quarter.
Hedge Funds Weigh In On Parabilis Medicines
Hedge funds have recently modified their holdings of the stock. Alphabet Inc. bought a new stake in shares of Parabilis Medicines in the 2nd quarter worth about $134,647,000. General Catalyst Group Management LLC purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $43,818,000. WINTON GROUP Ltd purchased a new stake in shares of Parabilis Medicines during the 2nd quarter valued at about $955,000. Squarepoint Ops LLC bought a new position in shares of Parabilis Medicines in the 2nd quarter valued at about $1,327,000. Finally, ICONIQ Capital LLC bought a new position in shares of Parabilis Medicines in the 2nd quarter valued at about $9,580,000.
About Parabilis Medicines
Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.
Featured Stories
- Five stocks we like better than Parabilis Medicines
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Parabilis Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parabilis Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
